Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Cipla    CIPLA   INE059A01026

CIPLA

(CIPLA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Cipla : Screening Solution for Active Pharmaceutical Ingredients

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/25/2019 | 03:01am EDT

Cipla Ltd upgrades its OEL compliant plant with the installation of the Russell Compact Airlock Sieve®

New Delhi, India, August 25, 2019 --(PR.com)-- Screening equipment is an integral part of most pharmaceutical processes and usually with the primary role to ensure ingredients and finished products are quality assured during production and before use or dispatch. When processing active pharmaceutical ingredients (API’s), the occupational exposure limit (OEL) has a significant part to play in the design of a process to ensure operators are not at risk to exposure. Therefore when Cipla Ltd built their OEL compliant plant at their Goa factory in 2005, having a vibro sifter that would ensure product quality and integrity were maintained without compromising the safety of their operators was essential.

In recent years, the pharmaceutical industry has seen a growing demand for products that require API’s and with the introduction of highly potent API’s (HPAPI’s), the concern for operator’s safety due to the adverse effects related to the handling of dangerous compounds is becoming more prevalent. Although a range of personal protective equipment (PPE) is widely available, this can only reduce exposure levels rather than eliminate them. Therefore, having certified plant equipment that can help reduce OEL levels must be considered an advantage not only to improve the working environment of operators but also to reduce costs associated with sophisticated PPE and dust containment systems.

Cipla’s new OEL compliant plant was built for the manufacture of a new highly potent drug and as with nearly all processes handling pharmaceutical powders, to ensure specification and quality were upheld a number of sieving operations were required. Firstly, on incoming raw materials to remove any oversized contamination and secondly after granulation to remove undersized particulates.

It was the task of Tapas Datta, factory manager of Cipla plant in Goa, to source a suitable vibro sifter to meet their stringent requirements. Due to the vibrating action of a sieve, dust can be generated very easily and therefore the need for a high containment sieve was required. It was during its showcase at an exhibition in 2005 when he came across the OEL level 5 sieve offered by Russell Finex. Known as the Russell Compact Airlock Sieve®, it utilizes a pneumatic clamping system, which, combined with its patented Twist Lock Inflate (TLI) technology, provides a uniform dust tight seal.

The relationship between Russell Finex and Cipla started in 2001 after purchasing their first circular vibro sifter. To date, the Goa site has multiples of Russell screeners positioned in a variety of production lines carrying out various check screening and grading applications.

The plant has been in operation for over 3 years and Cipla have been looking at ways to improve the process further. Although the cGMP design of the screener is based on clean lines making sanitation easier, reducing the exposure of operators to products during clean down of the sieve can be achieved by retrofitting the Russell WIP system. This spray ball system allows an even spray on the product contact parts to wet the components prior to dismantling the sieve improving handling of the components during clean down.

Speak to a sales engineer today to learn how Russell Finex can provide the right solution to your pharmaceutical production needs.

Contact Information:
Russell Finex Sieves & Filters Pvt.
Kumar Saurabh
+91 8928063881
Contact via Email
http://www.russellfinex.in/

Read the full story here: https://www.pr.com/press-release/792887

Press Release Distributed by PR.com

Copyright © 2019 PR.com and its licensors , source US Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CIPLA
08/26CIPLA : Breathe Free Lanka partners Novartis in Sri Lanka to provide Ultibro Bre..
AQ
08/25CIPLA : Screening Solution for Active Pharmaceutical Ingredients
AQ
08/22CIPLA : Breathe Free Lanka partners Novartis to provide Ultibro Breezhaler
AQ
07/31CIPLA : Ex-dividend day for final dividend
FA
07/29CIPLA : Alvotech and Cipla gulf into a partnership for the commercialization of ..
AQ
07/25CIPLA : USA furthers AMR stewardship with acquisition of key anti-infective ZEMD..
AQ
07/22CIPLA : InvaGen receives final approval for generic version of Pfizer's Lyrica
AQ
05/28CIPLA : Pharmaceutical Major Cipla Acquires 26 Percent Stake in AMPSolar
AQ
05/27CIPLA : Pharmaceutical Major Cipla Acquires 26 Percent Stake in AMPSolar
AQ
05/22CIPLA : Q4 net profit more than doubles to Rs 358 crore
AQ
More news
Financials (INR)
Sales 2020 173 B
EBIT 2020 23 088 M
Net income 2020 17 374 M
Debt 2020 25 950 M
Yield 2020 0,69%
P/E ratio 2020 20,9x
P/E ratio 2021 17,1x
EV / Sales2020 2,25x
EV / Sales2021 1,90x
Capitalization 364 B
Chart CIPLA
Duration : Period :
Cipla Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CIPLA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 547,63  INR
Last Close Price 452,05  INR
Spread / Highest target 43,8%
Spread / Average Target 21,1%
Spread / Lowest Target -2,89%
EPS Revisions
Managers
NameTitle
Umang Vohra Chief Executive Officer, MD & Director
Yusuf Khwaja Hamied Non-Executive Chairman
Raju Subramanyam Global Head-Operations
Kedar Upadhye Global Chief Financial Officer
Mustafa Khwaja Hamied Non-Executive Vice-Chairman
Sector and Competitors
1st jan.Capitalization (M$)
CIPLA-11.33%5 194
OTSUKA HOLDINGS CO LTD6.58%23 627
SUN PHARMACEUTICAL INDUSTRIES-2.29%14 052
ONO PHARMACEUTICAL CO., LTD.-9.03%9 317
SHANGHAI FOSUN PHARMACEUTICAL GROUP16.24%9 289
ZHEJIANG NHU CO LTD--.--%6 789